Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Holy grail stuff!
Regen BioPharma, Inc. Receives Positive Data From Preclinical Studies of Its Small Molecule NR2F6 ModulatorsFont
8:14 AM ET 9/20/16 | PR Newswire
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) today announced completion of experiments demonstrating immunological effects of its novel NR2F6 small molecule modulators. These experiments were conducted in collaboration with Dr. Xiaojing Ma, Professor of Microbiology and Immunology at Weill Cornell Medical College.
The experiments revealed that administration of Regen's proprietary compounds RG-NA01, RG-NI01 and RG-NI02 prevented cells of the immune system from producing the inflammatory factors interleukin-2, interferon-gamma, tumor necrosis factor-alpha and, importantly, interleukin-17a. These factors are critically involved in the immune response found in autoimmune diseases such as rheumatoid arthritis and psoriasis.
The company is currently developing small molecule drugs that target NR2F6 and either inhibit production of these factors or, in other cases, stimulate their production. The goal is to have a series of compounds that can modulate the immune system up or down.
Regen has recently filed a composition of matter patent application covering these novel NR2F6 small molecule modulators. NR2F6 is a molecular switch which controls genes associated with the immune response.
"We are delighted to discover that our lead compounds have a cellular effect, even though these compounds are not optimized yet," said Harry M. Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "These preclinical experiments firmly support our initial screening data which discovered these compounds. Now, it is a matter of optimizing these compounds to improve their efficacy. To date, no one in the world has reported the discovery of molecules, natural or synthetic, which activate or inhibit NR2F6 except Regen."
"The significance of these preclinical studies is that the data support our belief that controlling NR2F6 is key in treating autoimmune diseases such as arthritis by activating NR2F6. Additionally, the data suggest that by inhibiting NR2F6, these compounds can be used to treat cancer. In lay terms, if we turn the "light switch" on it causes NR2F6 to suppress the immune system thus potentially allowing treatment of rheumatoid arthritis and other autoimmune diseases. If we turn off the "light switch" we can cause the immune cells to be activated and kill cancer cells," stated David Koos, PhD, Chairman and CEO of Regen BioPharma Inc. "There are miles to go before we are finished but, these series of studies with Dr. Xiaojing Ma are very important. Regen believes we are on the verge of something extremely powerful in treating both autoimmunity and cancer."
right place at right time? what does that mean?
whoever THEY are....still a real nice piece!
100k....yeah right! once again who the hell would pay that?
WOW, actually a great piece! If that's a pump, I am all in!!!!
-40% aint nothing!
looks like a team of ihub pumpers got their grubby paws on this too.
I cannot access the write-up....
100k??????? who is paying that?????? it sure as crap aint the company!
curious what their disclaimer says...can you post that too?
can you post it...I am curious
If there is a shorty, he's in trouble obviously!
no doubt!!!!!!!!!!!!!
getting weird! now....MM's trying to spook up some selling, this is gonna POP upwards big time!
yeah, this volume is telling!!!!
crazy good volume!!! and price action....RIIIIIIP!
Pref's should start running now too!
look out above!!!
today should be real nice!
BINGO!
Regen BioPharma, Inc. Responds to FDA on dCellVax Gene-Silenced Breast Cancer Immunotherapy
Company Advances Development of Second Generation Immuno-Oncology Cellular Drug
08:00 ET from Regen BioPharma Inc.
SAN DIEGO, California, September 14, 2016 /PRNewswire/ --
Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), announced today submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer. The package submitted contained preclinical experiments as well as details of the proposed clinical trial. Results of the studies clearly demonstrated that the approach outlined, using siRNA to silence a key enzyme related to inhibition of the immune system, is effective at stimulating the type of immune response associated with known checkpoint inhibitors.
The enzyme silenced is Indoleamine 2,3-dioxygenase (IDO) , an enzyme that is overexpressed in some cancers and which suppresses immune system response against the cancer. The Company believes it has supplied the additional data and clarifications the FDA requested.
"Because dCellVax is a personalized cell therapy product aimed at activating the immune system of patients with metastatic breast cancer, we are excited to potentially have a product to deliver to patients who at the moment have no other options," said Dr. David Koos, CEO of Regen BioPharma.
"dCellVax is comprised of cells extracted from the patient's own circulating immune cells and processed using a proprietary method so as to activate these immune cells in such a way that they can attack cancer cells. Studies in animal and human immune cells by Regen and other groups have shown that the cells in dCellVax are highly active and secrete the same cytokines that immune cells known to kill cancer cells do. Thus, we are optimistic that this treatment will be useful in patients with cancer."
The proposed dCellVax clinical trial involves generation of patient-specific immune stimulatory cells termed "dendritic cells" that are modified by gene-silencing so as to lose expression of the immune checkpoint gene IDO. Ten patients with advanced breast cancer will be treated in the proposed clinical trial.
"dCellVax is one of the programs we are developing to activate the immune system in order to allow the body to kill cancer. Immune modulation, both inhibitory and stimulatory, is unlocking many novel ways to have the human body heal itself. dCellVax is only one of our immune modulatory products that we expect to bring to market in the future. The data package we sent to the FDA is an important step in this process," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma Inc.
Regen BioPharma, Inc. Responds to FDA on dCellVax Gene-Silenced Breast Cancer Immunotherapy
Company Advances Development of Second Generation Immuno-Oncology Cellular Drug
08:00 ET from Regen BioPharma Inc.
SAN DIEGO, California, September 14, 2016 /PRNewswire/ --
Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), announced today submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer. The package submitted contained preclinical experiments as well as details of the proposed clinical trial. Results of the studies clearly demonstrated that the approach outlined, using siRNA to silence a key enzyme related to inhibition of the immune system, is effective at stimulating the type of immune response associated with known checkpoint inhibitors.
The enzyme silenced is Indoleamine 2,3-dioxygenase (IDO) , an enzyme that is overexpressed in some cancers and which suppresses immune system response against the cancer. The Company believes it has supplied the additional data and clarifications the FDA requested.
"Because dCellVax is a personalized cell therapy product aimed at activating the immune system of patients with metastatic breast cancer, we are excited to potentially have a product to deliver to patients who at the moment have no other options," said Dr. David Koos, CEO of Regen BioPharma.
"dCellVax is comprised of cells extracted from the patient's own circulating immune cells and processed using a proprietary method so as to activate these immune cells in such a way that they can attack cancer cells. Studies in animal and human immune cells by Regen and other groups have shown that the cells in dCellVax are highly active and secrete the same cytokines that immune cells known to kill cancer cells do. Thus, we are optimistic that this treatment will be useful in patients with cancer."
The proposed dCellVax clinical trial involves generation of patient-specific immune stimulatory cells termed "dendritic cells" that are modified by gene-silencing so as to lose expression of the immune checkpoint gene IDO. Ten patients with advanced breast cancer will be treated in the proposed clinical trial.
"dCellVax is one of the programs we are developing to activate the immune system in order to allow the body to kill cancer. Immune modulation, both inhibitory and stimulatory, is unlocking many novel ways to have the human body heal itself. dCellVax is only one of our immune modulatory products that we expect to bring to market in the future. The data package we sent to the FDA is an important step in this process," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma Inc.
Regen BioPharma, Inc. Responds to FDA on dCellVax Gene-Silenced Breast Cancer Immunotherapy
Company Advances Development of Second Generation Immuno-Oncology Cellular Drug
08:00 ET from Regen BioPharma Inc.
SAN DIEGO, California, September 14, 2016 /PRNewswire/ --
Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), announced today submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer. The package submitted contained preclinical experiments as well as details of the proposed clinical trial. Results of the studies clearly demonstrated that the approach outlined, using siRNA to silence a key enzyme related to inhibition of the immune system, is effective at stimulating the type of immune response associated with known checkpoint inhibitors.
The enzyme silenced is Indoleamine 2,3-dioxygenase (IDO) , an enzyme that is overexpressed in some cancers and which suppresses immune system response against the cancer. The Company believes it has supplied the additional data and clarifications the FDA requested.
"Because dCellVax is a personalized cell therapy product aimed at activating the immune system of patients with metastatic breast cancer, we are excited to potentially have a product to deliver to patients who at the moment have no other options," said Dr. David Koos, CEO of Regen BioPharma.
"dCellVax is comprised of cells extracted from the patient's own circulating immune cells and processed using a proprietary method so as to activate these immune cells in such a way that they can attack cancer cells. Studies in animal and human immune cells by Regen and other groups have shown that the cells in dCellVax are highly active and secrete the same cytokines that immune cells known to kill cancer cells do. Thus, we are optimistic that this treatment will be useful in patients with cancer."
The proposed dCellVax clinical trial involves generation of patient-specific immune stimulatory cells termed "dendritic cells" that are modified by gene-silencing so as to lose expression of the immune checkpoint gene IDO. Ten patients with advanced breast cancer will be treated in the proposed clinical trial.
"dCellVax is one of the programs we are developing to activate the immune system in order to allow the body to kill cancer. Immune modulation, both inhibitory and stimulatory, is unlocking many novel ways to have the human body heal itself. dCellVax is only one of our immune modulatory products that we expect to bring to market in the future. The data package we sent to the FDA is an important step in this process," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma Inc.
prepare for the Friday Rally!
prepare for the Friday Rally!
Lander, drop some mid-day news!!!
It means indicators/chart looks great and BUY it!!!
great post and thx Schuller!
Proud as in about to make a nice commission check!
Looking awesome!!!
MORE!
WOW...crank up the excite-o-meter!
yep...expecting a lunchtime bonanza of 2 splacking!
224M on bid now...more than ask!, price is 2, not 1 though!
TELL THAT TO THE 152m ON THE BID NOW!
news now and these three tickets will go bonkers!!!
what's that mean?
cause bmsn is undervalued based on its ownership of Regen....1's were candy!
great!! and thanks for that!